+ Watch DNDN
on My Watchlist
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
No reason for a 20% upspike on Dendreon other than someone thought it got "too cheap" and shorts had to do some covering. I can't find any fundamentals that would suggest Dendreon share price should increase from here. Although it's Provenge is a worthy achievement, as expected it couldn't productize it and it never got the buyout it sought. One trick pony with a drug that's expensive, difficult to manufacture and difficult to get doctors to prescribe. Burn rate continues with no end in sight. Short term CAPS play, will not ride it down too far.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions